{
  "docId": "019de073-ec7b-760b-b9a4-60ceb97e90d9",
  "docSlug": "fef1528177829f37cded553f72a56b72",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 44 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 44,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "Includes a line chart showing market share trends for Calquence vs competitors in the BTKi class.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-ec7b-760b-b9a4-60ceb97e90d9/17",
  "deckHref": "/decks/019de073-ec7b-760b-b9a4-60ceb97e90d9",
  "deckJsonHref": "/decks/019de073-ec7b-760b-b9a4-60ceb97e90d9.json",
  "deckAnchorHref": "/decks/019de073-ec7b-760b-b9a4-60ceb97e90d9#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.36,
        "y": 0.48
      },
      "kind": "chart",
      "text": "BTKi class 1L CLL US NBRx",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8801f226-73a9-4d18-8c08-af43fe7eef20",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.95,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "disclaimer",
      "text": "Source: Based on internal analysis by AstraZeneca UK Limited using data from the following source: IQVIA US Medical Claims Data (Dx) and IQVIA US Longitudinal Access and Adjudication Data (LAAD)...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c81c0582-2b61-411f-9190-9319fc3a1054",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.03,
        "y": 0.35
      },
      "kind": "list",
      "text": "Imfinzi: TOPAZ-1 (First-and-only immunotherapy + chemotherapy in BTC, NCCN category 1 preferred, US approval under Priority Review); HIMALAYA (US approval for Imjudo + Imfinzi in unresectable HCC)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "00e5d109-f072-48f1-bc40-bf0d0f743080",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.67,
        "y": 0.35
      },
      "kind": "list",
      "text": "Enhertu: DESTINY-Breast04 (HER2-low mBC post ET and chemo, US approval two weeks after submission acceptance, Rapid uptake in post-chemo population); DESTINY-Lung02 (US approval in HER2m NSCLC, Validates efficacy beyond typical HER2-targeted diseases)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b00a06da-ce1d-4fbe-94b8-d4d7ae9021ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.35,
        "y": 0.35
      },
      "kind": "list",
      "text": "Calquence: ELEVATE-TN/ASCEND (US NBRx share in CLL >55%, US tablet approval); EU increasing share of BTKi class in CLL following launches in 2021",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd605049-8946-4a33-990f-461373263e7c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Strong global launch performance",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b68f42e4-3336-47fa-9525-84cd05a9c642",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Oncology: Q3 2022",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3bd0b0fa-5935-49a7-a929-6e864fe647c3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 9,
      "beatId": "5274d4de-7082-4c1d-91f5-9d6035fb8af2",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "Slides 9-20 provide detailed results and strategic investments.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}